MedTrace Logo

Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSD

NCT06724809 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2025-12-19

No results posted yet for this study

Summary

The primary objective of this study is to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of Eculizumab in Chinese Adults with Neuromyelitis Optica Spectrum Disorders (NMOSD).

Conditions

  • NMOSD
  • Neuromyelitis Optica Spectrum Disorders

Interventions

DRUG

eculizumab

Participants will receive eculizumab by intravenous (IV) infusion for 52 weeks.

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Alexion Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Xiangjun Chen, M.D · Huashan Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
130 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-16
Primary Completion
2026-12-07
Completion
2026-12-07

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06724809 on ClinicalTrials.gov